Effects of uremic serum and uremic toxins on hepatic uptake of digoxin

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 576-582

  Tsujimoto, Masayuki ^a   Kinoshita, Yuri ^b   Hirata, Sumio ^c   Otagiri, Masaki ^c   Ohtani, Hisakazu ^d   Sawada, Yasufumi ^d  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Digoxin; Hepatic uptake; Renal failure; Uremic toxin

Indexed keywords

DIGOXIN; HIPPURIC ACID; INDICAN; INDOLEACETIC ACID; PARA CRESOL; PROPIONIC ACID DERIVATIVE; UREMIC TOXIN; 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC ACID; 4-CRESOL; CRESOL; FURAN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CONTROLLED STUDY; DRUG UPTAKE; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; KIDNEY FAILURE; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TEMPERATURE; UREMIA; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; LIVER; METABOLISM; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CRESOLS; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FURANS; HEPATOCYTES; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER; MALE; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; RENAL DIALYSIS; UREMIA;

EID: 55349108227     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181838077     Document Type: Article

References (48)

1. Lesaffer G, de Smet R, Lameire N, et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant. 2000;15:50-57.
2. Fagugli RM, de Smet R, Buoncristiani U, et al. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis. 2002;40:339-347.
3. Dhondt A, Vanholder R, van Biesen W, et al. The removal of uremic toxins. Kidney Int. 2000;76:S47-S59.
4. Laouari D, Yang R, Veau C, et al. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol. 2001;280:F636-F645.
5. Holzer B, Stieger B, Folkers G, et al. Differential regulation of basolateral and canalicular transporter expression in rat liver in chronic renal failure. Clin Pharmacol Ther. 2005;77:34.
6. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial. 2003;16:45-50.
7. Rane A, Villeneuve JP, Stone WJ, et al. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther. 1978;24:199-207.
8. Smet R, Vogeleere P, van Kaer J, et al. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. J Chromatogr A. 1999;847:141-153.
9. Leblond FA, Petrucci M, Dube P., et al. Downregulation of intestinal cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2002;13:1579-1585.
10. Yu SY, Chung HC, Kim EJ, et al. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. J Pharm Pharmacol. 2002;54:1687-1692.
11. Huang ZH, Murakami T, Okochi A, et al. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol. 2000;406:453-460.
12. Sun H, Huang Y, Frassetto L, et al. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004;32:1239-1246.
13. Sun H, Huang Y, Okuchi H, et al. Uremic toxins inhibit hepatic uptake of eprosartan. Clin Pharmacol Ther. 2005,77:2.
14. Hsiang B, Zhu Y, Wang Z, et al. A novel human organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274:37161-37168.
15. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139-146.
16. Niemi M, Backman JT, Kajosaari LI, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004;14:429-440.
17. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005;77:468-478.
18. Lennemas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42:1141-1160.
19. Shitara Y, Itoh T, Sato H, et al. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003;304:610-616.
20. Shitara Y, Hirano M, Sato H, et al. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311:228-236.
21. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-463.
22. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33:537-546.
23. Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther. 2005;78:388-399.
24. Bi YA, Kazolias D, Duignan DM. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab Dispos. 2006;34:1658-1665.
25. Ito S, Nasu R, Tsujimoto M, et al. Effect of macrolide antibiotics on uptake of digoxin into rat liver. Biopharm Drug Dispos. 2007;28:113-123.
26. Kakyo M, Sakagami H, Nishio T, et al. Immunohistochemical distribution and functional characterization of an organic anion transporting polypeptide 2 (oatp2). FEBS Lett. 1999;445:343-346.
27. Konig J, Cui Y, Nies AT, et al. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 2000;275:23161-23168.
28. Tsutsumi Y, Maruyama T, Takadate A, et al. Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin. Pharm Res. 1999;16:916-923.
29. Mizuma T, Horie T, Awazu S. The effect of albumin on the uptake of bromosulfophthalein by isolated rat hepatocytes. J Pharmacobio-dyn. 1985;8:90-94.
30. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 2001;297:861-867.
31. Yamazaki M, Suzuki H, Hanano M, et al. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 1993;264:G36-G44.
32. Vanholder R, de Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-1943.
33. Okudaira K, Sawada Y, Sugiyama Y, et al. Effects of basic drugs on the hepatic transport of cardiac glycosides in rats. Biochem Pharmacol. 1998;37:2949-2955.
34. Lowry OH, Rosebrough NJ, Fair AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
35. Yamaoka K, Tanigawara Y, Nakagawa T, et al. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobio-dyn. 1981;4:879-885.
36. Ananthanarayanan M, Ng OC, Boyer JL, et al. Characterization of cloned rat liver Na (+)-bile acid cotransporter using peptide and fusion protein antibodies. Am J Physiol. 1994;267:G637-G643.
37. Noe B, Hagenbuch B, Stieger B, et al. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci U S A. 1997;94:10346-10350.
38. Carton V, Hagenbuch B, Hagenbuch N, et al. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major fall-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett. 2000;474:242-245.
39. Simonson GD, Vincent AC, Roberg KJ, et al. Molecular cloning and characterization of a novel liver-specific transport protein. J Cell Sci. 1994;107:1065-1072.
40. Meyer-Wentrup F, Karbach U, Gorboulev V, et al. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun. 1998;248:673-678.
41. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001;120:525-533.
42. Kodawara T, Masuda S, Wakasugi H, et al. Organic anion transporter oatpla4-mediated interaction between digoxin and amiodarone in the liver. Pharm Res. 2002;19:738-743.
43. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function and regulation. Physiol Rev. 2003;83:633-671.
44. Kullak-Ublick GA, Hagenbuch B, Stieger B, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995;109:1274-1282.
45. Konig J, Cui Y, Nies AT, et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol. 2000;278:G156-G164.
46. Sun W, Wu RR, van Poelje PD, et al. Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 2001;283:417-422.
47. Zhang L, Dresser MJ, Gray AT, et al. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51:913-921.
48. Liu L, Mak E, Tirana RG, et al. Vascular binding, blood flow, transporter, and enzyme interactions on the processing of digoxin in rat liver. J Pharmacol Exp Ther. 2005;315:433-448.